N-caffeoyltryptamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-caffeoyltryptamine
• 英文别名: (E)-N-(2-(1H-indol-3-yl)ethyl)-3-(3,4-dihydroxyphenyl)acrylamide；3-(3,4-dihydroxyphenyl)-N-[2-(1H-indol-3-yl)ethyl]prop-2-enamide
• 化学式: C₁₉H₁₈N₂O₃
• 分子量: 322.364
• InChiKey: LNKPAQNDSCOUPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  85.4
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  色胺 、 咖啡酸 在 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.08h， 以69%的产率得到N-caffeoyltryptamine
  参考文献：
  名称：

  Radical scavenging and antibacterial activity of caffemides against gram positive, gram negative and clinical drug resistance bacteria

  摘要：

  A new series of caffemide were synthesized and their antioxidant and antibacterial activities were explored. Antioxidant and antibacterial activities were measured of different structures of caffemide containing different functional groups. Anti-oxidative caffemides 1b and 1g showed significantly higher activity against different bacteria with MIC values less than 50 mu ml. These anti-oxidative and antibacterial properties of caffemides might be helpful for the treatment of secondary infections and discovery of new antibiotics. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2016.10.089

文献信息

• Radical scavenging and antibacterial activity of caffemides against gram positive, gram negative and clinical drug resistance bacteria
  作者：Kaushik Misra、Himadri Sekhar Maity、Ahindra Nag、Avinash Sonawane

  DOI：10.1016/j.bmcl.2016.10.089

  日期：2016.12

  A new series of caffemide were synthesized and their antioxidant and antibacterial activities were explored. Antioxidant and antibacterial activities were measured of different structures of caffemide containing different functional groups. Anti-oxidative caffemides 1b and 1g showed significantly higher activity against different bacteria with MIC values less than 50 mu ml. These anti-oxidative and antibacterial properties of caffemides might be helpful for the treatment of secondary infections and discovery of new antibiotics. (C) 2016 Elsevier Ltd. All rights reserved.